India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Rybelsus is a key driver, capturing 69% of the market. The introduction of Mounjaro and upcoming launch of Wegovy are expected to further accelerate growth, driven by rising lifestyle diseases and increased willingness to pay for treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QXA8Fyi
via IFTTT